Sleep drug could unlock secrets of depression and anxiety
NCT ID NCT07267559
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how daridorexant, a sleep medication that blocks the brain chemical orexin, affects emotional processing and learning in 62 healthy adults. Participants take a single dose of the drug or a placebo and then complete tasks that measure emotional responses and learning. The goal is to better understand orexin's role in mental health conditions like depression and anxiety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daridorexant (brand name Quviviq), a sleep medication that blocks orexin, a brain chemical involved in sleep, emotion, and stress.
What this could lead to
If successful, this study could reveal how orexin influences emotional and cognitive processes, potentially pointing toward new treatments for depression and anxiety.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. It only measures brain responses, not actual treatment effects, so results may not translate to real-world therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEARNING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Psychiatry, University of Oxford
RECRUITINGOxford, OX3 7JX, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••